Profile data is unavailable for this security.
About the company
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
- Revenue in USD (TTM)1.12bn
- Net income in USD440.30m
- Incorporated1987
- Employees749.00
- LocationNovavax Inc21 Firstfield RdGAITHERSBURG 20878United StatesUSA
- Phone+1 (240) 268-2000
- Fax+1 (302) 636-5454
- Websitehttps://www.novavax.com/?locale=US
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.47bn | 31.00 | -- | 18.24 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Nuvation Bio Inc | 26.75m | -217.48m | 1.52bn | 291.00 | -- | 4.59 | -- | 56.66 | -0.6399 | -0.6399 | 0.0787 | 0.9508 | 0.0456 | -- | 6.34 | 121,581.80 | -37.08 | -33.42 | -41.58 | -34.49 | 54.26 | -- | -813.07 | -11,132.31 | 8.39 | -- | 0.3842 | -- | -- | -- | -649.24 | -- | -24.47 | -- |
| Ardelyx Inc | 407.32m | -61.60m | 1.53bn | 489.00 | -- | 9.10 | -- | 3.75 | -0.2576 | -0.2576 | 1.69 | 0.6832 | 0.8691 | 2.03 | 6.29 | 832,965.30 | -13.14 | -27.52 | -15.98 | -35.02 | 90.29 | 87.82 | -15.12 | -42.28 | 4.11 | -2.04 | 0.5485 | -- | 22.09 | 121.90 | -57.40 | -- | 35.72 | -- |
| Sionna Therapeutics Inc | 0.00 | -75.27m | 1.53bn | 59.00 | -- | 4.97 | -- | -- | -1.70 | -1.70 | 0.00 | 6.86 | 0.00 | -- | -- | 0.00 | -29.42 | -- | -30.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.01 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 263.50m | -390.98m | 1.54bn | 975.00 | -- | 2.21 | -- | 5.85 | -1.12 | -1.12 | 0.7376 | 1.70 | 0.289 | 3.64 | 3.47 | 270,258.50 | -42.88 | -48.97 | -50.03 | -56.18 | 28.66 | -- | -148.38 | -453.71 | 2.83 | -- | 0.0014 | -- | 60.60 | -- | -5.05 | -- | -6.28 | -- |
| Novavax Inc | 1.12bn | 440.30m | 1.55bn | 749.00 | 3.93 | -- | 3.30 | 1.38 | 2.41 | 2.41 | 6.37 | -0.7858 | 0.821 | 7.20 | 10.46 | 1,499,972.00 | 32.17 | -28.14 | 78.45 | -190.63 | 93.50 | -- | 39.19 | -45.53 | 2.10 | 24.98 | 2.06 | -- | 64.69 | 18.76 | 334.83 | -- | -36.68 | -- |
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.55bn | 155.00 | -- | 8.02 | -- | 23.28 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.55bn | 123.00 | -- | 4.67 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.57bn | 26.00 | -- | 8.28 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.59bn | 28.00 | -- | 3.28 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Biohaven Ltd | 0.00 | -738.82m | 1.60bn | 274.00 | -- | 27.21 | -- | -- | -6.96 | -6.96 | 0.00 | 0.3922 | 0.00 | -- | -- | 0.00 | -138.54 | -125.47 | -185.54 | -162.51 | -- | -- | -- | -- | -- | -- | 0.821 | -- | -- | -- | 12.71 | -- | -23.32 | -- |
| Intellia Therapeutics Inc | 67.67m | -412.69m | 1.61bn | 377.00 | -- | 2.36 | -- | 23.75 | -3.83 | -3.83 | 0.6246 | 5.77 | 0.0666 | -- | 7.53 | 179,498.70 | -40.60 | -35.53 | -45.39 | -39.16 | -- | -- | -609.85 | -872.47 | -- | -- | 0.00 | -- | 16.92 | 3.13 | 20.49 | -- | -20.63 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.61bn | 123.00 | -- | 59.15 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.63bn | 317.00 | -- | 2.99 | -- | 19.36 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
Data as of Mar 04 2026. Currency figures normalised to Novavax Inc's reporting currency: US Dollar USD
47.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Shah Capital Management, Inc.as of 31 Dec 2025 | 14.56m | 8.96% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 14.20m | 8.74% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 11.34m | 6.98% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 9.52m | 5.86% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 5.99m | 3.69% |
| UBS Securities LLCas of 31 Dec 2025 | 4.79m | 2.95% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 4.54m | 2.79% |
| Millennium Management LLCas of 31 Dec 2025 | 4.47m | 2.75% |
| BofA Securities, Inc.as of 31 Dec 2025 | 3.75m | 2.31% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.72m | 2.29% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
